まとめ
リウマチ性疾患に対する長期のクロロクイン治療は,網膜の変化を引き起こす可能性があります. しかし,眼性毒性のリスクは受け入れられるほど低く,ほとんどの患者で視力の悪化は最小限に留まっています.
科学分野:
- オフタルモロジック (眼科)
- レウマトロジーの病理学
- 薬理学 薬理学とは
背景:
- クロロクインは,様々なリウマチ病の長期間の治療法です.
- クロロキンの長期使用は,潜在的な眼毒性,特に網膜病変と関連しています.
- 慢性的なクロロクイン治療を受けている患者では,副作用のモニタリングが不可欠です.
研究 の 目的:
- 長期クロロクイン療法を受けたリウマチ病患者の網膜の変化の発生率と特徴を調査する.
- クロロクインの投与量,治療期間,患者の年齢,および網膜病変の発生の間の関係を評価する.
- 網膜病変の進行と,時間の経過とともに視力の鋭さへの影響を評価する.
主な方法:
- クロロクインで治療された関節リウマチ症の222人の患者の眼科データを遡及分析した.
- 網膜の発見と患者の年齢,クロロキンの累積投与量,治療期間との相関関係.
- 視覚の鋭さ評価と網膜病変の徴候のモニタリングを含む眼科レビュー.
主要な成果:
- 網膜の変化は,クロロクインの長期治療を受けた222人の患者のうち22人 (9.9%) で観察されました.
- 網膜の変化の発生は,患者の年齢,クロロクインの総投与量,治療期間と有意に関連していました.
- 視力の悪化とともに網膜症の進行を経験した患者は1人だけであったが,他の患者は正常な視力を維持した.
結論:
- リウマティック疾患の患者におけるクロロクイン関連網膜症は,比較的まれにみられる.
- クロロクイン・レチノパシーによる重要な視覚障害のリスクは,長期使用でも低い.
- クロロクイン療法に関連する目の毒性リスクは,一般的に,関節リウマチ症の管理のために受け入れられるほど低いと考えられています.
関連する概念動画
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:23Rheumatic Heart Disease I: Introduction
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
01:20Rheumatic Heart Disease IV: Nursing Management
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...